KẾT QUẢ ĐIỀU TRỊ UNG THƯ ĐẠI TRỰC TRÀNG TÁI PHÁT DI CĂN BẰNG PHÁC ĐỒ FOLFIRI TẠI BỆNH VIỆN UNG BƯỚU NGHỆ AN

Abstract

Aims: Evaluate treament results and some toxicities in metastasic recurrent colorectal cancer patients treated with FOLFIRI at Nghe An Oncology Hospital. Patients and methods: descriptive study with longitudinal follow-up on 40 patients with a confirmed diagnosis of metastatic recurrent colorectal cancer, no longer amenable to radical surgery, and treated. using the FOLFIRI regimen at Nghe An Oncology Hospital from September 2017 to September 2023. Results: Complete response rate after 12 cycles reached 35,0%, of which 2,5% of patients achieved complete response and 32,5% of patients achieved partial response, Stable disease accounted for 22,5% of patients. However, 42,5% of patients had progressive disease. Median progression-free survival time of the study patient population was 11,1 months (6,1- 16,0). Factors that prolong progression-free survival of patients with metastatic recurrent colorectal cancer are the number of metastatic sites and response to chemotherapy. Side effects mainly include neutropenia (57,5%), diarrhea (57,5%), vomiting (40,0%), mostly grade 1 and 2.